The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
β 2 -Agonist Therapy in Lung Disease
Open accessAbstract
β2-Agonists are effective bronchodilators due primarily to their ability to relax airway smooth muscle (ASM). They exert their effects via their binding to the active site of β2-adrenoceptors on ASM, which triggers a signaling cascade that results in a number of events, all of which contribute to relaxation of ASM. There are some differences between β2-agonists. Traditional inhaled short-acting β2-agonists albuterol, fenoterol, and terbutaline provide rapid as-needed symptom relief and short-term prophylactic protection against bronchoconstriction induced by exercise or other stimuli. The twice-daily β2-agonists formoterol and salmeterol represent important advances. Their effective bronchodilating properties and long-term improvement in lung function offer considerable clinical benefits to patients. More recently, a newer β2-agonist (indacaterol) with a longer pharmacodynamic half-life has been discovered, with the hopes of achieving once-daily dosing. In general, β2-agonists have an acceptable safety profile, although there is still controversy as to whether long-acting β2-agonists may increase the risk of asthma mortality. In any case, they can induce adverse effects, such as increased heart rate, palpitations, transient decrease in PaO2, and tremor. Desensitization of β2-adrenoceptors that occurs during the first few days of regular use of β2-agonist treatment may account for the commonly observed resolution of the majority of these adverse events after the first few doses. Nevertheless, it can also induce tolerance to bronchoprotective effects of β2-agonists and has the potential to reduce bronchodilator sensitivity to them. Some novel once-daily β2-agonists (olodaterol, vilanterol, abediterol) are under development, mainly in combination with an inhaled corticosteroid or a long-acting antimuscarinic agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Global strategy for asthma management and prevention: GINA executive summary
Bateman, E. D., Hurd, S. S., Barnes, P. J., Bousquet, J., Drazen, J. M., FitzGerald, M., Gibson, P., Ohta, K., O'Byrne, P., Pedersen, S. E., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00138707 · Cited by 3,203
The Salmeterol Multicenter Asthma Research Trial
Nelson, H. S., Weiss, S. T., Bleecker, E. R., Yancey, S. W., & Dorinsky, P. M. (2006) · Chest · doi:10.1378/chest.129.1.15 · Cited by 1,114
Outcomes for COPD pharmacological trials: from lung function to biomarkers
Cazzola, M., MacNee, W., Martinez, F. J., Rabe, K. F., Franciosi, L. G., Barnes, P. J., Brusasco, V., Burge, P. S., Calverley, P. M. A., Celli, B. R., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00099306 · Cited by 858
Self-citationDevice Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines
Dolovich, M. B., Ahrens, R. C., Hess, D. R., Anderson, P., Dhand, R., Rau, J. L., Smaldone, G. C., & Guyatt, G. (2005) · Chest · doi:10.1378/chest.127.1.335 · Cited by 794
Regional Lung Deposition and Bronchodilator Response as a Function of β 2 -Agonist Particle Size
Usmani, O. S., Biddiscombe, M. F., & Barnes, P. J. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200410-1414oc · Cited by 578
Aerosol drug delivery: developments in device design and clinical use
Dolovich, M. B., & Dhand, R. (2011) · The Lancet · doi:10.1016/s0140-6736(10)60926-9 · Cited by 505
Pharmacology and Therapeutics of Bronchodilators
Cazzola, M., Page, C. P., Calzetta, L., & Matera, M. G. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004580 · Cited by 467
Self-citationCheung, D., Timmers, M. C., Zwinderman, A. H., Bel, E. H., Dijkman, J. H., & Sterk, P. J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210223271703 · Cited by 455
The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD
Cazzola, M., & Molimard, M. (2010) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2010.03.003 · Cited by 241
Self-citationcAMP regulation of airway smooth muscle function
Billington, C. K., Ojo, O. O., Penn, R. B., & Ito, S. (2013) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2012.05.007 · Cited by 240
Ducharme, F. M., Ni Chroinin, M., Greenstone, I., & Lasserson, T. J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005535.pub2 · Cited by 185
Ducharme, F. M., Ni Chroinin, M., Greenstone, I., & Lasserson, T. J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005533.pub2 · Cited by 185
Methodological issues in therapeutic trials of COPD
Suissa, S., Ernst, P., Vandemheen, K. L., & Aaron, S. D. (2008) · European Respiratory Journal · doi:10.1183/09031936.00098307 · Cited by 160
β2‐adrenoceptor agonists: current and future direction
Cazzola, M., Calzetta, L., & Matera, M. G. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01216.x · Cited by 158
Self-citationBattram, C., Charlton, S. J., Cuenoud, B., Dowling, M. R., Fairhurst, R. A., Farr, D., Fozard, J. R., Leighton-Davies, J. R., Lewis, C. A., McEvoy, L., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.098251 · Cited by 145
Long-term Safety and Efficacy of Indacaterol, a Long-Acting β2-Agonist, in Subjects With COPD
Chapman, K. R., Rennard, S. I., Dogra, A., Owen, R. J., Lassen, C., & Krämer, B. (2011) · CHEST Journal · doi:10.1378/chest.10-1830 · Cited by 135
Inhaled ??2-Adrenoceptor Agonists
Cazzola, M., Matera, M. G., & Donner, C. F. (2005) · Drugs · doi:10.2165/00003495-200565120-00001 · Cited by 135
Self-citationScheinin, M., Koulu, M., Laurikainen, E. A., & Allonen, H. O. (1987) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1987.tb03224.x · Cited by 125
van der Molen, T., & Cazzola, M. (2012) · Primary Care Respiratory Journal · doi:10.4104/pcrj.2011.00102 · Cited by 123
Self-citationTiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease
Chong, J., Karner, C., & Poole, P. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009157.pub2 · Cited by 110
Martínez, F. J., Donohue, J. F., & Rennard, S. I. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61047-7 · Cited by 103
Philipson, L. H. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.129702 · Cited by 99 · cited 1×
“β-AR stimulation in the liver induces glycogenolysis and raises blood sugar levels [30].”
BackgroundSlack, R. J., Barrett, V. J., Morrison, V. S., Sturton, R. G., Emmons, A. J., Ford, A. J., & Knowles, R. G. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.198481 · Cited by 99
Lombardi, D., Cuenoud, B. M., & Krämer, S. D. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.10.001 · Cited by 99
Bouyssou, T., Casarosa, P., Naline, E., Pestel, S., Konetzki, I., Devillier, P., & Schnapp, A. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167007 · Cited by 95
Novel bronchodilators for the treatment of chronic obstructive pulmonary disease
Matera, M. G., Page, C. P., & Cazzola, M. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.04.003 · Cited by 93
Self-citationSykes, D. A., & Charlton, S. J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01639.x · Cited by 74
Lötvall, J. O., Bateman, E. D., Bleecker, E. R., Busse, W. W., Woodcock, A. A., Follows, R., Lim, J., Stone, S., Jacques, L., & Haumann, B. (2012) · European Respiratory Journal · doi:10.1183/09031936.00121411 · Cited by 73
Agonist efficacy and receptor desensitization: from partial truths to a fuller picture
Charlton, S. J. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00352.x · Cited by 67
24-hour Bronchodilation following a single dose of the novel β2-agonist olodaterol in COPD
van Noord, J. A., Smeets, J. J., Drenth, B. M., Rascher, J., Pivovarova, A., Hamilton, A., & Cornelissen, P. J. G. (2011) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2011.07.006 · Cited by 60
Aparici, M., Gómez-Angelats, M., Vilella, D., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.193284 · Cited by 53
Novel cAMP signalling paradigms: therapeutic implications for airway disease
Billington, C. K., & Hall, I. P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01719.x · Cited by 51
Safety of long-acting β agonists for the treatment of asthma: clearing the air
Rodrigo, G. J., & Castro-Rodríguez, J. A. (2011) · Thorax · doi:10.1136/thx.2010.155648 · Cited by 48
Approaches to stepping up and stepping down care in asthmatic patients
Thomas, A., Lemanske, R. F., & Jackson, D. J. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.07.014 · Cited by 47
Tremor and β2-adrenergic agents: Is it a real clinical problem?
Cazzola, M., & Matera, M. G. (2011) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2011.12.004 · Cited by 47
Self-citationHanania, N. A. (2008) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2007.12.004 · Cited by 43
O’Byrne, P. M., van der Linde, J., Cockcroft, D. W., Gauvreau, G. M., Brannan, J. D., FitzGerald, M., Watson, R. M., Milot, J., Davis, B. E., O'Connor, M., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.08.047 · Cited by 43
Clinically meaningful outcomes in patients with chronic obstructive pulmonary disease
ZuWallack, R., Haggerty, M. C., & Jones, P. W. (2004) · The American Journal of Medicine Supplements · doi:10.1016/j.amjmed.2004.10.020 · Cited by 37
Call for withdrawal of LABA single-therapy inhaler in asthma
Beasley, R. W., Perrin, K., Weatherall, M., & Wijesinghe, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61158-0 · Cited by 36
Cost-Effectiveness Analysis of Formoterol Versus Salmeterol in Patients with Asthma
Mölken, M. R., van Doorslaer, E. K. A., & Till, M. D. (1998) · PharmacoEconomics · doi:10.2165/00019053-199814060-00007 · Cited by 36
An update on bronchodilators in Phase I and II clinical trials
Cazzola, M., Rogliani, P., Segreti, A., & Matera, M. G. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.710602 · Cited by 36
Self-citationCazzola, M., Noschese, P., Michele, F. D., D’Amato, M., & Matera, M. G. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2005.04.024 · Cited by 28
Self-citationOliver, A. J., Quinn, D., Goldfrad, C. H., van Hecke, B., Ayer, J., & Boyce, M. J. (2012) · Clinical and Translational Allergy · doi:10.1186/2045-7022-2-11 · Cited by 17
Weatherall, M., Wijesinghe, M., Perrin, K., & Beasley, R. W. (2010) · Journal of Asthma · doi:10.3109/02770900903556439 · Cited by 7
Metadata
- Authors
- Cazzola, M., Page, C. P., Rogliani, P., & Matera, M. G.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-04-01
- Volume
- 187
- Issue
- 7
- Pages
- 690-696
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2057335633
- Cited by
- 262
- References
- 45
- FWCI
- 21.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.